Search Results - "Paterson, Alexander HG"

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial by Paterson, Alexander HG, Prof, Anderson, Stewart J, Prof, Lembersky, Barry C, MD, Fehrenbacher, Louis, MD, Falkson, Carla I, MD, King, Karen M, MD, Weir, Lorna M, MD, Brufsky, Adam M, Prof, Dakhil, Shaker, MD, Lad, Thomas, MD, Baez-Diaz, Luis, MD, Gralow, Julie R, MD, Robidoux, André, MD, Perez, Edith A, Prof, Zheng, Ping, MD, Geyer, Charles E, MD, Swain, Sandra M, Prof, Costantino, Joseph P, Prof, Mamounas, Eleftherios P, MD, Wolmark, Norman, Prof

“…Summary Background Bisphosphonates are thought to act through the osteoclast by changing bone microenvironment. Previous findings of adjuvant clodronate trials…”
Get full text

Abstract P2-18-02: Fractures in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial (ClinicalTrials.gov Identifier: NCT00127205) by Yung, Rachel L (MD), Miao, Jieling, Paterson, Alexander HG, Clemons, Mark, Dees, Elizabeth C, Ingle, James N, Falkson, Carla I, Barlow, William, Hortobagyi, Gabriel N, Gralow, Julie R

“…Background: Evidence from randomized trials, including a recent meta-analysis, suggests that adjuvant bisphosphonates can decrease recurrence and death in…”
Get full text

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer by Samuel, Jacobs A, Wilson, John W, Bandos, Hanna, Elledge, Richard M, Robidoux, André, Fehrenbacher, Louis, Ward, Patrick J, Polikoff, Johnathan, Brufsky, Adam M, Provencher, Louise, Paterson, Alexander HG, Hamm, John T, Carolla, Robert L, Baez-Diaz, Luis, Rastogi, Priya, Julian, Thomas B, Wickerham, D Lawrence, Swain, Sandra M, Geyer, Charles E, Mamounas, Eleftherios P, Wolmark, Norman

“…Background NSABP B-36 was originally designed as a 2X2 factorial randomized study to compare 6 cycles of FEC-100 with 4 cycles of standard AC with or without…”
Get full text

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide by Ganz, Patricia A, Wilson, John W, Bandos, Hanna, Robidoux, André, Paterson, Alexander HG, Polikoff, Johnathan, Baez-Diaz, Luis, Brufsky, Adam M, Fehrenbacher, Louis, Mangalik, Aroop, Ward, Patrick J, Provencher, Louise, Hamm, John T, Stella, Philip J, Carolla, Robert L, Margolese, Richard G, Shibata, Henry R, Perez, Edith A, Wolmark, Norman

“…Background NSABP B-36 compares 6 cycles of FEC-100 with 4 cycles of standard AC in pts with node-negative breast cancer. As reported separately, no significant…”
Get full text

Should women with early hormone-responsive breast cancer be switched from tamoxifen to anastrozole? by Paterson, Alexander HG

Get full text

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women : A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1 by SAWKA, C. A, PRITCHARD, K. I, SHELLEY, W, DEBOER, G, PATERSON, A. H. G, MEAKIN, J. W, SUTHERLAND, D. J. A

“…We concluded a randomized crossover trial comparing tamoxifen 40 mg daily with ovarian ablation for treatment of metastatic breast cancer in premenopausal…”
Get full text